504 related articles for article (PubMed ID: 33966550)
1. RNA therapeutics for mood disorders: current evidence toward clinical trials.
Le Marois M; Tzavara E; Ibrahim EC; Blin O; Belzeaux R
Expert Opin Investig Drugs; 2021 Jul; 30(7):721-736. PubMed ID: 33966550
[TBL] [Abstract][Full Text] [Related]
2. The Ethics of Clinical Trials Research in Severe Mood Disorders.
Nugent AC; Miller FG; Henter ID; Zarate CA
Bioethics; 2017 Jul; 31(6):443-453. PubMed ID: 28503892
[TBL] [Abstract][Full Text] [Related]
3. Immune-based strategies for mood disorders: facts and challenges.
Colpo GD; Leboyer M; Dantzer R; Trivedi MH; Teixeira AL
Expert Rev Neurother; 2018 Feb; 18(2):139-152. PubMed ID: 29179585
[TBL] [Abstract][Full Text] [Related]
4. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
5. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
[TBL] [Abstract][Full Text] [Related]
6. The Translational Potential of Non-coding RNAs and Multimodal MRI Data Sets as Diagnostic and Differential Diagnostic Biomarkers for Mood Disorders.
Todeva-Radneva A; Aryutova K; Kandilarova S; Paunova R; Stoyanov D
Curr Top Med Chem; 2021; 21(11):949-963. PubMed ID: 34355686
[TBL] [Abstract][Full Text] [Related]
7. Practical application of digital therapeutics in people with mood disorders.
Orsolini L; Longo G; Volpe U
Curr Opin Psychiatry; 2024 Jan; 37(1):9-17. PubMed ID: 37972954
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Drugs for Mood Disorders.
Peedicayil J; Kumar A
Prog Mol Biol Transl Sci; 2018; 157():151-174. PubMed ID: 29933949
[TBL] [Abstract][Full Text] [Related]
9. Circadian genes, rhythms and the biology of mood disorders.
McClung CA
Pharmacol Ther; 2007 May; 114(2):222-32. PubMed ID: 17395264
[TBL] [Abstract][Full Text] [Related]
10. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
Malhi GS; Bassett D; Boyce P; Bryant R; Fitzgerald PB; Fritz K; Hopwood M; Lyndon B; Mulder R; Murray G; Porter R; Singh AB
Aust N Z J Psychiatry; 2015 Dec; 49(12):1087-206. PubMed ID: 26643054
[TBL] [Abstract][Full Text] [Related]
11. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.
McIntyre RS; Alsuwaidan M; Goldstein BI; Taylor VH; Schaffer A; Beaulieu S; Kemp DE;
Ann Clin Psychiatry; 2012 Feb; 24(1):69-81. PubMed ID: 22303523
[TBL] [Abstract][Full Text] [Related]
12. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
Soria V; González-Rodríguez A; Huerta-Ramos E; Usall J; Cobo J; Bioque M; Barbero JD; García-Rizo C; Tost M; Monreal JA; ; Labad J
Psychoneuroendocrinology; 2018 Jul; 93():8-19. PubMed ID: 29680774
[TBL] [Abstract][Full Text] [Related]
13. Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.
de Sousa RT; Loch AA; Carvalho AF; Brunoni AR; Haddad MR; Henter ID; Zarate CA; Machado-Vieira R
Neuropsychopharmacology; 2017 Mar; 42(4):787-800. PubMed ID: 27510426
[TBL] [Abstract][Full Text] [Related]
14. Physical Activity Modulates Common Neuroplasticity Substrates in Major Depressive and Bipolar Disorder.
Phillips C
Neural Plast; 2017; 2017():7014146. PubMed ID: 28529805
[TBL] [Abstract][Full Text] [Related]
15. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.
Schaffer A; McIntosh D; Goldstein BI; Rector NA; McIntyre RS; Beaulieu S; Swinson R; Yatham LN;
Ann Clin Psychiatry; 2012 Feb; 24(1):6-22. PubMed ID: 22303519
[TBL] [Abstract][Full Text] [Related]
16. Add-on high frequency deep transcranial magnetic stimulation (dTMS) to bilateral prefrontal cortex in depressive episodes of patients with major depressive disorder, bipolar disorder I, and major depressive with alcohol use disorders.
Rapinesi C; Kotzalidis GD; Ferracuti S; Girardi N; Zangen A; Sani G; Raccah RN; Girardi P; Pompili M; Del Casale A;
Neurosci Lett; 2018 Apr; 671():128-132. PubMed ID: 29454034
[TBL] [Abstract][Full Text] [Related]
17. Cytokine polymorphisms in the pathophysiology of mood disorders.
Clerici M; Arosio B; Mundo E; Cattaneo E; Pozzoli S; Dell'osso B; Vergani C; Trabattoni D; Altamura AC
CNS Spectr; 2009 Aug; 14(8):419-25. PubMed ID: 19890236
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Seizure Therapy for Unipolar and Bipolar Depression: A Systematic Review.
Cretaz E; Brunoni AR; Lafer B
Neural Plast; 2015; 2015():521398. PubMed ID: 26075100
[TBL] [Abstract][Full Text] [Related]
19. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project.
McIntyre RS; Soczynska JK; Cha DS; Woldeyohannes HO; Dale RS; Alsuwaidan MT; Gallaugher LA; Mansur RB; Muzina DJ; Carvalho A; Kennedy SH
J Affect Disord; 2015 Feb; 172():259-64. PubMed ID: 25451425
[TBL] [Abstract][Full Text] [Related]
20. The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder.
Mandelli L; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU; Serretti A
Adv Ther; 2017 Mar; 34(3):713-724. PubMed ID: 28144920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
